Affimed N.V. (AFMD): Price and Financial Metrics

Affimed N.V. (AFMD): $6.30

-0.09 (-1.41%)

POWR Rating

Component Grades













Add AFMD to Watchlist
Sign Up

Industry: Biotech


of 506

in industry


  • AFMD scores best on the Value dimension, with a Value rank ahead of 80.66% of US stocks.
  • The strongest trend for AFMD is in Momentum, which has been heading down over the past 47 weeks.
  • AFMD ranks lowest in Momentum; there it ranks in the 4th percentile.

AFMD Stock Summary

  • For AFMD, its debt to operating expenses ratio is greater than that reported by merely 6.54% of US equities we're observing.
  • With a year-over-year growth in debt of -68.54%, Affimed NV's debt growth rate surpasses only 5.17% of about US stocks.
  • Revenue growth over the past 12 months for Affimed NV comes in at 400.05%, a number that bests 97.91% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to AFMD, based on their financial statements, market capitalization, and price volatility, are AUTL, ALPN, VCNX, FULC, and SYRS.
  • AFMD's SEC filings can be seen here. And to visit Affimed NV's official web site, go to

AFMD Price Target

For more insight on analysts targets of AFMD, see our AFMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.75 Average Broker Recommendation 1.25 (Strong Buy)

AFMD Stock Price Chart Interactive Chart >

Price chart for AFMD

AFMD Price/Volume Stats

Current price $6.30 52-week high $11.74
Prev. close $6.39 52-week low $3.09
Day low $6.20 Volume 885,880
Day high $6.40 Avg. volume 2,140,854
50-day MA $6.56 Dividend yield N/A
200-day MA $7.35 Market Cap 619.21M

Affimed N.V. (AFMD) Company Bio

Affimed NV is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The company was founded in 2000 and is based in Heidelberg, Germany.

AFMD Latest News Stream

Event/Time News Detail
Loading, please wait...

AFMD Latest Social Stream

Loading social stream, please wait...

View Full AFMD Social Stream

Latest AFMD News From Around the Web

Below are the latest news stories about Affimed NV that investors may wish to consider to help them evaluate AFMD as an investment opportunity.

New Strong Sell Stocks for September 13th

AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.

Yahoo | September 13, 2021

Affimed NV (NasdaqGM:AFMD) (AFMD) Q2 2021 Earnings Call Transcript

On the call today, we have the following members of our management team, Dr. Adi Hoess, our Chief Executive Officer; Andreas Harstrick, our Chief Medical Officer; Arndt Schottelius, our Chief Scientific Officer; Wolfgang Fischer, our Chief Operating Officer; and Angus Smith, our Chief Financial Officer. Today's discussion contains projections and forward-looking statements regarding future events.

Yahoo | September 8, 2021

Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -171.43% and -13.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | September 8, 2021

Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

AFM13 monotherapy: Enrollment is on track and expected to be completed in the first half of 2022.AFM13 combination with NK cells: All three dose escalation cohorts are fully enrolled with no dose limiting toxicities observed; additional patients are being enrolled at the highest dose level to confirm safety and generate additional efficacy data; data update expected at a scientific conference in Q4 2021.AFM24 monotherapy: Based on current data, doses used in cohorts 5 (320 mg) and 6 (480 mg) are

Yahoo | September 8, 2021

Affimed N.V. hosts conference call for investors

The company, Affimed N.V., is set to host investors and clients on a conference call on 9/8/2021 8:02:21 PM. The call comes after the company''s earnings, which are set to be announced on 9/8/2021.Investors, or members of the public who wish to dial in, can join the call by visiting

Business Insider Markets | September 6, 2021

Read More 'AFMD' Stories Here

AFMD Price Returns

1-mo 9.95%
3-mo -23.54%
6-mo -19.02%
1-year 65.79%
3-year 44.00%
5-year 107.24%
YTD 8.25%
2020 112.41%
2019 -11.90%
2018 139.23%
2017 -27.78%
2016 -74.72%

Continue Researching AFMD

Want to see what other sources are saying about Affimed NV's financials and stock price? Try the links below:

Affimed NV (AFMD) Stock Price | Nasdaq
Affimed NV (AFMD) Stock Quote, History and News - Yahoo Finance
Affimed NV (AFMD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9773 seconds.